IntraBiotics Shares Rise on FDA Decision
- Share via
From Associated Press
IntraBiotics Pharmaceuticals Inc. stock more than doubled to a 52-week high after federal regulators gave fast-track status to the company’s only drug, iseganan, to reduce the onset of pneumonia in people on mechanical ventilators.
Shares of Palo Alto-based IntraBiotics traded up 110%, or $4.10, at $7.80 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
